Safety of Dipeptidyl Peptidase 4 Inhibitors for Treatment of Type 2 Diabetes

E-ISSN： 2212-3911|6|5|304-309

ISSN： 1574-8863

Source： Current Drug Safety, Vol.6, Iss.5, 2011-11, pp. : 304-309

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Potential for combination of dipeptidyl peptidase‐4 inhibitors and sodium‐glucose co‐transporter‐2 inhibitors for the treatment of type 2 diabetes

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 7, 2015-07 ,pp. : 616-621

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (ELECTRONIC), Vol. 42, Iss. 10, 2015-10 ,pp. : 999-1024

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dipeptidyl peptidase‐4 inhibitors and the risk of community‐acquired pneumonia in patients with type 2 diabetes

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 4, 2015-04 ,pp. : 379-385

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes

DIABETES/METABOLISM: RESEARCH AND REVIEWS (ELECT), Vol. 34, Iss. 2, 2018-02 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes

By Hanefeld Markolf Herman Gary A. Wu Mei Mickel Carolyn Sanchez Matilde Stein Peter P.

Current Medical Research and Opinion, Vol. 23, Iss. 6, 2007-06 ,pp. : 1329-1339

Informa Healthcare

Access to resources Recommend Favorite